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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The objectives of this review are:
• to estimate the relative effectiveness and safety profiles for methods of management of miscarriage;
• to provide a ranking of the available methods according to their effectiveness and safety profile.
B A C K G R O U N D
Description of the condition
Miscarriage is the most common cause of pregnancy loss. An
estimated 15% to 20% of pregnancies will end in miscarriage,
with 25% of women experiencing a miscarriage in their lifetime
(Alberman 1992). This can have an emotional and a physical im-
pact on both women and their partners that can last well beyond
the pregnancy (Conway 2000; Geller 2001; Neugebauer 1997).
Miscarriage is generally defined as the spontaneous loss of a preg-
nancy before 24 weeks’ gestation (Shiers 2003). Most miscarriages
happen in the first 14 weeks, and are known as early miscar-
riages (Alberman 1992). The clinical signs of miscarriage are vagi-
nal bleeding, usually with abdominal pain. Miscarriage can lead
to serious morbidity, including haemorrhage and infection, and
evendeath, particularly in low-income countries (MBRRACE-UK
2016).
Description of the intervention
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Miscarriage can be managed expectantly, medically (with tablets)
or surgically. Although historically miscarriages were often treated
with a surgical procedure, women now have the options of expec-
tant or medical management. However, there is uncertainty about
their relative effectiveness and risks.
Surgical methods have traditionally been used to manage early
miscarriage. Dilatation and curettage uses sharp metal curettage
that is often performed in an operating room under regional or
general anaesthesia. Sharp curettage is often performed after di-
latation of the cervix. Even though it is a relatively simple proce-
dure, it does carry a small chance of serious adverse events, such as
anaesthetic complications, infection, uterine perforation and Ash-
erman’s syndrome. Suction curettage (electrical or manual vacuum
aspiration) has replaced sharp curettage in high-income countries
and has a well-documented safety profile and is included in the
essential surgical equipment by the World Health Organization
(WHO) for obstetric care at first referral level (WHO 2009). Even
so, it is less commonly used in low-middle income countries due
to lack of equipment and experience. Surgical methods can be
combined with an agent to prepare (or ripen) the cervix to avoid
the risks of injury from cervical dilation. Commonly used agents
includemechanical and pharmacological dilators. Themechanical
dilators may use osmotic cervical rods, Foley catheters or laminaria
to dilate the cervix. The pharmacological dilators cause cervical
ripening by softening and dilation of the cervix.
Medical methods of management of miscarriage include various
agents. Misoprostol is a synthetic prostaglandin E1 analogue that
induces cervical ripening and uterine contraction. It is water-sol-
uble and heat stable (Davies 2001). Oral and sublingual routes
have the advantage of rapid onset of action, while the vaginal and
rectal routes result in prolonged activity and greater bioavailability
(Schaff 2005). However, it is associated with side-effects such as
diarrhoea, abdominal pain, nausea and vomiting, shivering and
pyrexia (Tunçalp 2012). Other synthetic prostaglandins are avail-
able, such as gemeprost or dinoprost, but these agents are less fre-
quently used in this setting.
Mifepristone is a progesterone antagonist that interferes with the
production or functioning of progesterone and can initiate shed-
ding of pregnancy tissue. Mifepristone has been used alone for
terminating unwanted pregnancies, but more frequently is used in
combination with misoprostol to manage early miscarriage. It is
considered to be more useful in women with missed miscarriages
where a non-viable pregnancy is identified on ultrasound scan,
without associated pain and bleeding (also known as early fetal
demise, delayedmiscarriage or silent miscarriage). In women with
incomplete miscarriage with a diagnosed non-viable pregnancy in
which bleeding has begun, but some pregnancy tissue remains in
the uterus, the anti-progesterone effect of mifepristone is consid-
ered less useful and treatment is aimed to stimulate uterine con-
tractility often with misoprostol alone.
Why it is important to do this review
Several Cochrane reviews have compared an individual method
for managing miscarriage with another method or with expectant
management (Kim 2017; Nanda 2012; Tuncalp 2010; Webber
2015). However, a standard pairwise meta-analysis can only com-
pare two drugs that have been directly compared in head-to-head
trials (direct evidence). In the absence of a single high-quality ran-
domised controlled trial that compares all methods for manag-
ing miscarriage, uncertainty remains about which is the most ef-
fective. For the management of miscarriage with multiple com-
peting treatment methods, not all of which have been directly
compared, a network meta-analysis may be better able to allow
for comparisons about which method is most effective (Caldwell
2005; Caldwell 2010). A network meta-analysis simultaneously
pools all the available direct and indirect evidence on relative treat-
ment effects, within a single coherent analysis. Indirect evidence is
obtained by inferring the relative effectiveness of two competing
methods through a common comparator. Thus a network meta-
analysis produces estimates of the relative effects of each method
compared with every other in a network, even though some pairs
may not have been directly compared, and has the potential to
reduce the uncertainty in treatment effect estimates (Caldwell
2005). It also allows for the calculation of the probability that each
method is the best for any given outcome. Network meta-analysis
can additionally be used to identify gaps in the evidence base.
O B J E C T I V E S
The objectives of this review are:
• to estimate the relative effectiveness and safety profiles for
methods of management of miscarriage;
• to provide a ranking of the available methods according to
their effectiveness and safety profile.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all randomised controlled comparisons or cluster
trials that assess the effectiveness or safety of methods for mis-
carriage management. Quasi-randomised trials will be eligible for
inclusion. We will exclude non-randomised trials.
2Methods for managing miscarriage: a network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of participants
We will consider for inclusion all studies that include women who
are being treated for early miscarriage (pregnancy loss at less than
14 weeks), diagnosed by ultrasound or clinically alone. We will
includewomenwith bothmissed and incompletemiscarriage. Also
we will consider for inclusion studies conducted in all settings. We
will include all women regardless of age.
Types of interventions
We will include the following interventions: dilatation plus sharp
curettage, suction curettage, suction curettage with cervical prepa-
ration, misoprostol alone, and mifepristone plus misoprostol ver-
sus expectant management or placebo.
If we identify interventions in the included studies of which we
are not aware, we will consider including them after we assess their
comparability with those interventions named above.
Wewill stratify all interventions according to the gestation, type of
miscarriage and drug strategy (dose, route or regimen), to detect
inequalities that could affect comparative effectiveness. We will
include regimens irrespective of their dose as long as it is in the
therapeutic range.Multi-arm trials that compare different dosages,
regimens or routes of one drug, but also compare those versus
another drug, will be included. We will merge the intervention
arms of different dosages, regimens or routes of the same drug to-
gether for the global analysis of all outcomes and will treat them as
separate independent comparisons only for the relevant subgroup
analysis according to dosage, regimen and route of drug admin-
istration, while taking into account the correlation between the
comparisons. We will also include trials that compare exclusively
different dosages, regimens or routes of administration of the same
drug. The review will be restricted to studies that evaluate drugs
administered by healthcare professionals (Figure 1).
Figure 1. Network plot for management of miscarriage.
We will code the comparisons within a study as follows:
• expectant = any management that does not involve any
surgical or medical treatment;
• suction curettage = any surgical management that involves a
suction curette without any cervical preparation agents;
• suction curettage with cervical preparation = any surgical
management that involves a suction curette with cervical
preparation agents;
• dilatation plus sharp curettage = any surgical treatment
involving sharp metal curette;
• mifepristone plus misoprostol = any medical management
with the combined use of mifepristone plus misoprostol at any
dose, route or regimen;
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• misoprostol alone = any medical management with the use
of misoprostol alone at any dose, route or regime.
Participants in the network could in principle be randomised to
any of the methods being compared. For example, a woman with
an early miscarriage could be equally likely to be randomised to
manual vacuum aspiration, dilatation plus curettage, misopros-
tol, suction curettage, cervical preparation plus suction curettage,
mifepristone plus misoprostol or expectant management.
We will also include comparisons between different routes of ad-
ministration of medical treatment (e.g. oral versus vaginal), or be-
tween different drugs or doses of drug, or duration or timing of
treatment, if data exist and will be part of a subgroup analysis. We
also aim to compare cervical preparation drugs with each other
and compare different doses, routes and regimens of the same drug
with each other in a subgroup analysis if sufficient data exist.
Types of outcome measures
Primary outcomes
• Complete miscarriage: this is defined as evidence of
complete evacuation of uterine contents based on clinical
findings or ultrasound examination after a specific time period as
defined in the primary studies;
• composite outcome of death or serious complications (e.g.
uterine perforation, need for further life-saving procedures
including hysterectomy, blood transfusion or intensive care unit
admission).
Secondary outcomes
• Need for unplanned/emergency surgical procedure;
• pain scores (visual analogue scale);
• pelvic inflammatory disease, sepsis or endometritis;
• mean volumes of blood loss (mL);
• change in haemoglobin measurements before and after the
miscarriage;
• days of bleeding;
• cervical tear;
• women’s views/satisfaction;
• mean duration of hospital stay (days);
• re-admission to hospital;
• nausea;
• vomiting;
• diarrhoea;
• pyrexia;
• anxiety score;
• depression score.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We will search Cochrane Pregnancy and Childbirth’s Trials Regis-
ter by contacting their Information Specialist.
The Register is a database that contains over 22,000 reports of
controlled trials in the field of pregnancy and childbirth. For full
search methods used to populate the Cochrane Pregnancy and
Childbirth’s Trials Register, including the detailed search strategies
for CENTRAL, MEDLINE, Embase and CINAHL, the list of
handsearched journals and conference proceedings, and the list of
journals reviewed via the current awareness service, please follow
this link to the editorial information about Cochrane Pregnancy
and Childbirth in theCochrane Library and select the ‘Specialized
Register’ section from the options on the left side of the screen.
In brief, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Two people screen the search results and the full text of all rel-
evant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a specific
Cochrane Pregnancy and Childbirth review topic (or topics), and
is then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in amore specific search set that will be fully
accounted for in the relevant review sections (included studies, ex-
cluded studies, studies awaiting classification or ongoing studies).
In addition,wewill search ClinicalTrials.gov and theWorldHealth
Organization (WHO) International Clinical Trials Registry Plat-
form (ICTRP) for unpublished, planned and ongoing trial reports
using the terms listed in Appendix 1.
Searching other resources
Wewill retrieve additional relevant references cited in papers iden-
tified through the above search strategy. We will search for the full
texts of studies identified as abstracts. We will seek information
from primary authors to investigate whether these studies meet
eligibility criteria, and to obtain outcome and study data. If this is
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not possible, we will only include abstracts if we can extract suf-
ficient information to satisfy our eligibility criteria and the study
authors report the outcomes of interest. Trials that compare at least
two of the drugs are eligible and we shall search for all possible
comparisons formed by the drugs of interest.
We will search the reference lists of retrieved studies.
We will not apply any language or date restrictions.
Data collection and analysis
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors will independently assess for inclusion all the
potential studies we identify as a result of the search strategy. We
will resolve any disagreements through discussion or, if required,
we will consult a third review author. We will create a PRISMA
study flow diagram to map out the number of records identified,
included and excluded. We will list all studies excluded after full-
text assessment and their reasons for exclusion in a ’Characteristics
of excluded studies’ table.
Data extraction and management
We will design an electronic form in Microsoft Access software to
extract data. For eligible studies, two review authors will extract the
data using the agreed form. We will resolve discrepancies through
discussion or, if required, we will consult a third review author.
We will enter data into Review Manager 5 (RevMan 5) software
and will check for accuracy (RevMan 2014). When information
regarding any of the above is unclear, we will attempt to contact
the authors of the original reports to provide further details.
We will extract the following data.
Outcome data
From each included study we will extract the number of partici-
pants, the parity of participants, along with the inclusion and ex-
clusion criteria. We will also extract the interventions being com-
pared including the healthcare setting and type of anaesthesia used,
and their respective primary and secondary outcomes. We will ex-
tract all relevant arm level data (e.g. number of events and number
of participants for binary outcomes).
Data on potential effect modifiers
From each included study we will extract the following study,
intervention and population characteristics that may act as effect
modifiers:
• gestational age (≥ nine weeks versus greater than nine
weeks of gestation);
• type of miscarriage (incomplete versus missed miscarriage);
• dosage, regimen, and route of drug administration
(sublingual, rectal, oral).
Other data
From each included study we will extract the following additional
information:
• country or countries in which the study was performed;
• date of publication;
• type of publication (full text publication, abstract
publication, unpublished data);
• trial registration reference.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias for
each included study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreement by discussion or by involving a
third review author.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
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(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as at:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake.
We will assess methods as at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups or not exceeding 10% for
the primary outcomes of the review);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation or exceeding 10% for the primary outcomes of
the review);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; the study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we will assess the likely magni-
tude and direction of the bias and whether we consider it is likely
to impact on the findings.Wewill explore the impact of the level of
bias through undertaking sensitivity analyses (see the ’Sensitivity
analysis’ section).
Measures of treatment effect
For dichotomous data, we will present results as a summary risk
ratio with 95% confidence intervals (CIs). For continuous data,
we will use the mean difference if outcomes are measured in the
same way between trials. We will use the standardised mean dif-
ference to combine trials that measure the same outcome, but use
different methods. If the target parameter is the effect of change in
a continuousmeasure, such as the change in haemoglobin between
baseline and post-miscarriage, we will, where possible, account for
the within-patient correlation between baseline and post-miscar-
riage estimates (Dias 2013).
Relative treatment ranking
We will also estimate the ranking probabilities for all treatments
of being at each possible rank for each intervention (conditional
on the model and specified vague priors). Then we will obtain a
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treatment hierarchy using the surface under the cumulative rank-
ing curve (SUCRA). SUCRA can also be expressed as a percentage
of effectiveness or side-effects of a treatment that would be ranked
first without uncertainty. For primary outcomes, we will assess the
robustness of these findings in sensitivity analysis by considering
estimates of mean rank with 95% CIs. We will also present the
’Summary of findings’ tables using GRADEpro Guideline Devel-
opment Tool (GDT) software for each outcome. In the ’Sum-
mary of findings’ tables, we will follow the approach suggested by
Schünemann 2009 and Puhan 2014.
Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually randomised trials. Where necessary, we will adjust
their standard errors using the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Section 16.3.4
or 16.3.6) using an estimate of the intracluster correlation co-effi-
cient (ICC) derived from the trial (if possible), from a similar trial
or from a study of a similar population. If we use ICC values from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Cross-over trials are not eligible for this review.
Multi-arm trials
We will include multi-arm trials and we will account for the cor-
relation between the effect sizes in the network meta-analysis. We
will treat multi-arm studies as multiple independent comparisons
in pairwise meta-analyses.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
We will impute missing standard deviations and errors using stan-
dard techniques where possible (Higgins 2011).
For all outcomes, we will perform analyses, as far as possible, on
an intention-to-treat basis, i.e. we will attempt to include all par-
ticipants randomised to each group in the analyses, and we will
analyse all participants in the group to which they were allocated,
regardless of whether or not they received the allocated interven-
tion. The denominator for each outcome in each trial will be the
number randomised minus any participants whose outcomes are
known to be missing.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity
To evaluate the presence of clinical heterogeneity, we will generate
descriptive statistics for trial and study population characteristics
across all eligible trials that compare each pair of interventions.
We will assess the presence of clinical heterogeneity within each
pairwise comparison by comparing these characteristics.
Assessment of transitivity across treatment comparisons
We will assess the assumption of transitivity by comparing the
distribution of potential effect modifiers across the different pair-
wise comparisons. In this context we expect that the transitivity
assumption will hold assuming the following:
• the common treatment used to compare different
miscarriage management drugs indirectly is similar when it
appears in different trials (e.g. misoprostol is administered in a
similar way to in misoprostol versus suction curettage trials and
in misoprostol versus mifepristone plus misoprostol trials);
• all pairwise comparisons do not differ with respect to the
distribution of effect modifiers (e.g. the design and study
characteristics of suction curettage versus misoprostol trials are
similar to misoprostol versus mifepristone plus misoprostol
trials).
We will evaluate the assumption of transitivity epidemiologically
by comparing the clinical and methodological characteristics of
sets of studies grouped by treatment comparisons.
Assessment of statistical heterogeneity and inconsistency
Assumptions when estimating the heterogeneity
In standard pairwise meta-analyses we will estimate different het-
erogeneity variances for each pairwise comparison. In network
meta-analysis we will assume a common estimate for the hetero-
geneity variance across the different comparisons.
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Measures and tests for heterogeneity
We will assess statistically the presence of heterogeneity within
each pairwise comparison using the I² statistic and its 95%CI that
measures the percentage of variability that cannot be attributed to
random error.
We will base the assessment of statistical heterogeneity in the en-
tire network on the magnitude of the heterogeneity variance pa-
rameter (τ2) estimated from the network meta-analysis models.
For dichotomous outcomes we will compare the magnitude of the
heterogeneity variance with the empirical distribution as derived
by Turner (Turner 2012). We will also estimate a total I² statistic
value for heterogeneity in the network as described elsewhere.
Assessment of statistical inconsistency
The statistical agreement between the various sources of evidence
in a network of interventions (consistency) will be evaluated by
global and local approaches to complement the evaluation of tran-
sitivity.
Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally we will use the
loop-specific approach. This method evaluates the consistency as-
sumption in each closed loop of the network separately as the dif-
ference between direct and indirect estimates for a specific com-
parison in the loop (inconsistency factor). Then, the magnitude
of the inconsistency factors and their 95%CIs can be used to infer
about the presence of inconsistency in each loop. We will assume
a common heterogeneity estimate within each loop.
Global approaches for evaluating inconsistency
To check the assumption of consistency in the entire network we
will use the “design-by-treatment” model as described by Higgins
and colleagues (Higgins 2012). Thismethod accounts for different
sources of inconsistency that can occur when studies with different
designs (two-arm trials versus three-arm trials) give different results
aswell as disagreement betweendirect and indirect evidence.Using
this approach we will infer about the presence of inconsistency
from any source in the entire network based on a Chi² test. We
will perform the design-by-treatment model in STATA using the
mvmeta command (StataCorp 2011).
Inconsistency and heterogeneity are interweaved; to distinguish
between these two sources of variability we will employ the I²
statistic for inconsistency that measures the percentage of variabil-
ity that cannot be attributed to random error or heterogeneity
(within comparison variability).
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, we will aim to minimise the po-
tential impact of these biases by ensuring a comprehensive search
for eligible studies and by being alert to duplication of data. If
there are 10 or more studies in the network meta-analysis, we will
use a funnel plot to explore the possibility of small study effects
(a tendency for estimates of the intervention effect to be more
beneficial in smaller studies) and account for the fact that studies
estimate effects for different comparisons.
Data synthesis
Methods for direct treatment comparisons
We will perform standard pairwise meta-analyses using a random-
effects in the presence of substantial heterogeneity or fixed-effect
model in STATA for every treatment comparison (DerSimonian
1986).
Methods for indirect and mixed comparisons
We will perform network meta-analysis using a random-effects
model in STATA with the mvmeta command within the network
suite of commands for network meta-analysis (White 2015), and
other STATA commands for visualising and reporting results in
network meta-analysis (Chaimani 2015).
Subgroup analysis and investigation of heterogeneity
If we find important heterogeneity or inconsistency, or both, we
will explore the possible sources. If sufficient studies are available,
we will perform subgroup analyses by using the following effect
modifiers.
• gestational age (≥ nine weeks versus > nine weeks of
gestation);
• type of miscarriage (incomplete versus missed miscarriage);
• type of vacuum aspiration device used (electrical versus
manual vacuum aspiration);
• type of healthcare setting (inpatient versus outpatient);
• dosage, regimen, and route of drug administration
(sublingual, rectal, oral).
Wewill assess subgroupdifferences by evaluating the relative effects
and assessment of model fit for the primary outcomes.
Sensitivity analysis
For the primary outcomes we will perform sensitivity analysis for
the following:
• overall quality of the studies (low versus high risk of overall
bias);
• randomisation unit (cluster versus individual);
8Methods for managing miscarriage: a network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• different effect measures (risk ratio versus odds ratio);
• use of fixed-effect versus random-effects model;
• use of placebo versus expectant management.
We will assess differences by evaluating the relative effects and
assessment of model fit.
’Summary of findings’ table
We will assess the quality of the evidence using the GRADE ap-
proach as outlined in the GRADE handbook in order to assess the
quality of the body of evidence relating to the primary outcomes
for all comparisons including subgroups by type of miscarriage
(missed versus incomplete miscarriage):
• complete miscarriage;
• composite outcome of death or serious complications.
In order to create ’Summary of findings’ tables, we will use
GRADEpro GDT, to import data from RevMan 5 (RevMan
2014). We will produce a summary of the intervention effect and
a measure of quality for each of the above outcomes using the
GRADE approach. The GRADE approach uses five considera-
tions (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) to assess the quality of the body
of evidence for each outcome. The evidence can be downgraded
from ’high quality’ by one level for serious (or by two levels for
very serious) limitations, depending on assessments for risk of bias,
indirectness of evidence, serious inconsistency, imprecision of ef-
fect estimates or potential publication bias. We will follow the
approach suggested by Puhan 2014 and Schünemann 2009, and
provide estimates from the network meta-analysis.
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A P P E N D I C E S
Appendix 1. Search terms for WHO ICTRP and ClinicalTrials.gov
curettage AND miscarriage
misoprostol AND miscarriage
mifepristone AND miscarriage
vacuum AND miscarriage
expectant AND miscarriage
management AND miscarriage
surgical AND miscarriage
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